Interleukin 1 receptor-associated kinase M impairs host defense during pneumococcal pneumonia

Journal of Infectious Diseases

Volumn 205, Issue 12, 2012, Pages 1849-1857

  Van Der Windt, Gerritje J W ^a   Blok, Dana C ^a   Hoogerwerf, Jacobien J ^a   Lammers, Adriana J J ^a   De Vos, Alex F ^a   Van'T Veer, Cornelis ^a   Florquin, Sandrine ^a   Kobayashi, Koichi S ^b   Flavell, Richard A ^c   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

AIRWAY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; CELL TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFICIENCY; GROWTH INHIBITION; HOST RESISTANCE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3 DEFICIENCY; LETHALITY; LUNG ALVEOLUS MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PATHOGEN LOAD; PHAGOCYTOSIS; PRIORITY JOURNAL; RISK REDUCTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TISSUE LEVEL;

ANIMALS; BACTERIAL LOAD; DISEASE MODELS, ANIMAL; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LUNG; MICE; MICE, INBRED C57BL; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 84861551019     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis290     Document Type: Article

References (46)

1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-72.
2. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009; 374:1543-56.
3. Bernstein JM. Treatment of community-acquired pneumonia-IDSA guidelines. Infectious Diseases Society of America. Chest 1999; 115:9S-13S.
4. Ishii KJ, Koyama S, Nakagawa A, Coban C, Akira S. Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe 2008; 3:352-63.
5. Beutler BA. TLRs and innate immunity. Blood 2009; 113:1399-407.
6. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27:519-50.
7. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of Toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5:446-58.
8. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110:191-202.
9. Deng JC, Cheng G, Newstead MW, et al. Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J Clin Invest 2006; 116:2532-42.
10. van 't Veer C, van den Pangaart PS, van Zoelen MA, et al. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol 2007; 179:7110-20.
11. Wiersinga WJ, van't Veer C, van den Pangaart PS, et al. Immunosuppression associated with interleukin-1R-associated-kinase-M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Crit Care Med 2009; 37:569-76.
12. Lagler H, Sharif O, Haslinger I, et al. TREM-1 activation alters the dynamics of pulmonary IRAK-M expression in vivo and improves host defense during pneumococcal pneumonia. J Immunol 2009; 183:2027-36.
13. Rijneveld AW, Weijer S, Florquin S, et al. Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood 2004; 103:1702-9.
14. Dessing MC, Knapp S, Florquin S, de Vos AF, van der Poll T. CD14 facilitates invasive respiratory tract infection by Streptococcus pneumoniae. Am J Respir Crit Care Med 2007; 175:604-11.
15. van der Windt GJ, Hoogerwerf JJ, de Vos AF, Florquin S, van der Poll T. Osteopontin promotes host defense during Klebsiella pneumoniae-induced pneumonia. Eur Respir J 2010; 36:1337-45.
16. Knapp S, Wieland CW, van 't Veer C, et al. Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol 2004; 172:3132-8.
17. Wan CP, Park CS, Lau BH. A rapid and simple microfluorometric phagocytosis assay. J Immunol Methods 1993; 162:1-7.
18. Knapp S, Matt U, Leitinger N, van der Poll T. Oxidized phospholipids inhibit phagocytosis and impair outcome in Gram-negative sepsis in vivo. J Immunol 2007; 178:993-1001.
19. Miksa M, Komura H, Wu R, Shah KG, Wang P. A novel method to determine the engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester. J Immunol Methods 2009; 342:71-7.
20. Paterson GK, Mitchell TJ. Innate immunity and the pneumococcus. Microbiology 2006; 152:285-93.
21. Xie Q, Gan L, Wang J, Wilson I, Li L. Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth. Mol Immunol 2007; 44:3453-61.
22. Nakayama K, Okugawa S, Yanagimoto S, et al. Involvement of IRAK-M in peptidoglycan-induced tolerance in macrophages. J Biol Chem 2004; 279:6629-34.
23. Liu ZJ, Yan LN, Li XH, et al. Up-regulation of IRAK-M is essential for endotoxin tolerance induced by a low dose of lipopolysaccharide in Kupffer cells. J Surg Res 2008; 150:34-9.
24. Hassan F, Islam S, Tumurkhuu G, et al. Involvement of interleukin-1 receptor-associated kinase (IRAK)-M in Toll-like receptor (TLR) 7-mediated tolerance in RAW 264.7 macrophage-like cells. Cell Immunol 2009; 256:99-103.
25. Zacharioudaki V, Androulidaki A, Arranz A, Vrentzos G, Margioris AN, Tsatsanis C. Adiponectin promotes endotoxin tolerance in macrophages by inducing IRAK-M expression. J Immunol 2009; 182:6444-51.
26. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 2009; 30:475-87.
27. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991; 88:1747-54.
28. McCall CE, Grosso-Wilmoth LM, LaRue K, Guzman RN, Cousart SL. Tolerance to endotoxin-induced expression of the interleukin-1 beta gene in blood neutrophils of humans with the sepsis syndrome. J Clin Invest 1993; 91:853-61.
29. Ertel W, Kremer JP, Kenney J, et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 1995; 85:1341-7.
30. Volk HD, Reinke P, Docke WD. Clinical aspects: from systemic inflammation to "immunoparalysis." Chem Immunol 2000; 74:162-77.
31. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-50.
32. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008; 8:32-43.
33. Wesche H, Gao X, Li X, Kirschning CJ, Stark GR, Cao Z. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem 1999; 274:19403-10.
34. Albiger B, Sandgren A, Katsuragi H, et al. Myeloid differentiation factor 88-dependent signalling controls bacterial growth during colonization and systemic pneumococcal disease in mice. Cell Microbiol 2005; 7:1603-15.
35. Branger J, Knapp S, Weijer S, et al. Role of Toll-like receptor 4 in Gram-positive and Gram-negative pneumonia in mice. Infect Immun 2004; 72:788-94.
36. Malley R, Henneke P, Morse SC, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003; 100:1966-71.
37. Albiger B, Dahlberg S, Sandgren A, et al. Toll-like receptor 9 acts at an early stage in host defence against pneumococcal infection. Cell Microbiol 2007; 9:633-44.
38. Rijneveld AW, Florquin S, Branger J, Speelman P, Van Deventer SJ, van der Poll T. TNF-alpha compensates for the impaired host defense of IL-1 type I receptor-deficient mice during pneumococcal pneumonia. J Immunol 2001; 167:5240-6.
39. Kafka D, Ling E, Feldman G, et al. Contribution of IL-1 to resistance to Streptococcus pneumoniae infection. Int Immunol 2008; 20: 1139-46.
40. Lauw FN, Branger J, Florquin S, et al. IL-18 improves the early antimicrobial host response to pneumococcal pneumonia. J Immunol 2002; 168:372-8.
41. Lee KS, Scanga CA, Bachelder EM, Chen Q, Snapper CM. TLR2 synergizes with both TLR4 and TLR9 for induction of the MyD88-dependent splenic cytokine and chemokine response to Streptococcus pneumoniae. Cell Immunol 2007; 245:103-10.
42. Gauthier JF, Fortin A, Bergeron Y, Dumas MC, Champagne ME, Bergeron MG. Differential contribution of bacterial N-formylmethionyl-leucyl-phenylalanine and host-derived CXC chemokines to neutrophil infiltration into pulmonary alveoli during murine pneumococcal pneumonia. Infect Immun 2007; 75:5361-7.
43. van der Windt GJ, Hoogendijk AJ, Schouten M, et al. Osteopontin impairs host defense during pneumococcal pneumonia. J Infect Dis 2011; 203:1850-8.
44. Giebelen IA, Leendertse M, Florquin S, van der Poll T. Stimulation of acetylcholine receptors impairs host defence during pneumococcal pneumonia. Eur Respir J 2009; 33:375-81.
45. Dallaire F, Ouellet N, Bergeron Y, et al. Microbiological and inflammatory factors associated with the development of pneumococcal pneumonia. J Infect Dis 2001; 184:292-300.
46. Seki M, Kohno S, Newstead MW, et al. Critical role of IL-1 receptor-associated kinase-M in regulating chemokine-dependent deleterious inflammation in murine influenza pneumonia. J Immunol 2010; 184:1410-8.